title: Plasma protoporphyrin IX following administration of 5-aminolevulinic acid as a potential tumor marker.
abstract: Exogenously administered 5-aminolevulinic acid (ALA) is metabolized to protoporphyrin IX (PpIX), which specifically accumulates in cancer cells and emits red fluorescence by blue light irradiation. These phenomena are applied for the intraoperative diagnosis of cancer. Based on the fact that accumulated PpIX in cancer cells is exported extracellularly via the ATP-binding cassette transporter G2, we hypothesized that the measurement of plasma PpIX concentrations could be applied as a tumor marker for cancer screening. In the present study, the use of plasma samples from bladder cancer patients were evaluated as a tumor marker. ALA, 1.0 g, was orally administered to bladder cancer patients and healthy adults. The plasma concentration of PpIX was measured using a high-performance liquid chromatography system. The plasma PpIX concentration following ALA administration was significantly higher in bladder cancer patients than that in the healthy adults, suggesting the effectiveness of plasma PpIX analysis following ALA administration for cancer screening. Additionally, 4 h after ALA administration, plasma PpIX showed high sensitivity (94.4%) and high specificity (80.0%).
authors.affiliation: SBI Pharmaceuticals Co., Ltd., Izumi Garden Tower 20F, 1-6-1, Tokyo 106-6020, Japan.
authors.forename: Urara
authors.initials: U
authors.lastname: Ota
authors.affiliation: Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
authors.forename: Hideo
authors.initials: H
authors.lastname: Fukuhara
authors.affiliation: SBI Pharmaceuticals Co., Ltd., Izumi Garden Tower 20F, 1-6-1, Tokyo 106-6020, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ishizuka
authors.affiliation: SBI Pharmaceuticals Co., Ltd., Izumi Garden Tower 20F, 1-6-1, Tokyo 106-6020, Japan.
authors.forename: Fuminori
authors.initials: F
authors.lastname: Abe
authors.affiliation: Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
authors.forename: Chiaki
authors.initials: C
authors.lastname: Kawada
authors.affiliation: Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Tamura
authors.affiliation: SBI Pharmaceuticals Co., Ltd., Izumi Garden Tower 20F, 1-6-1, Tokyo 106-6020, Japan.
authors.forename: Tohru
authors.initials: T
authors.lastname: Tanaka
authors.affiliation: Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
authors.forename: Keiji
authors.initials: K
authors.lastname: Inoue
authors.affiliation: Department of Bioengineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Kanagawa 226-8501, Japan.
authors.forename: Shun-Ichiro
authors.initials: SI
authors.lastname: Ogura
authors.affiliation: Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
authors.forename: Taro
authors.initials: T
authors.lastname: Shuin
keywords: 5-aminolevulinic acid; plasma; protoporphyrin IX; tumor marker